Cystatin C Confirms the Canagliflozin eGFR Slope Benefit in CANPIONE

20260 citationsJournal Articlegold Open Access

Authors

Satoshi Miyamoto · Okayama University Hospital

Hiddo J.L. Heerspink · University Medical Center Groningen

Dick de Zeeuw · University Medical Center Groningen

Kota Sakamoto · Okayama University Hospital

Michihiro Yoshida · Okayama University Hospital

Masao Toyoda · Tokai University

Daisuke Suzuki

Abstract

Incorporating the eGFR-cystatin C slope analysis supports the robustness of the previous creatinine-based slope findings, suggesting that the eGFR-creatinine slope analysis retains reasonable clinical reliability in patients treated with sodium-glucose cotransporter 2 inhibitors (SGLT2is).

Topics & Keywords

Chronic Kidney Disease and Diabetes Diabetes Treatment and Management Gastrointestinal motility and disorders

UN Sustainable Development Goals

Climate action

Publication Details

Published in: Kidney International Reports

Volume 11, Issue 5, pp. 106374-106374

DOI: 10.1016/j.ekir.2026.106374

Field-Weighted Citation Impact: 0.00